Effects of taurine in glucose and taurine administration.
Taurine has several biological processes such as hypoglycemic action, antioxidation, detoxification, etc. To assess the effect of taurine administration on the guinea pigs with hyperglycemia, blood glucose, C-peptide levels together with morphologic alterations in the pancreatic ultrastructure were investigated in terms of hypoglycemic action and malondialdehyde and total sulfhydryl group levels with regard to oxidation-antioxidation relation. Animals were divided into four groups of six. Glucose supplementation group was administrated a single dose of glucose (400 mg/kg, i.p.) injection. Glucose and taurine supplementation group was administrated glucose treatment (a single dose, 400 mg/kg, i.p.) following taurine (a single dose, 200 mg/kg, i.p.). Taurine and glucose supplementation group was administered taurine treatment (a single dose, 200 mg/kg, i.p.) following glucose treatment (a single dose, 400 mg/kg, i.p.). Control animals received no treatment. Blood samples were collected at the end of the experiments for the determination of glucose, C-peptide (indicator of insulin secretion), lipid peroxidation (thiobarbituric acid reactive substances), and total sulfhydryl groups levels. Pancreatic tissue samples were then collected and processed for transmission electron microscopy. The findings showed that glucose supplementation following taurine administration significantly decreased blood glucose level by increasing C-peptide level and the pancreatic secretion stimulated morphologically and insignificantly changed thiobarbituric acid reactive substances and total sulfhydryl group levels. These observations suggest that taurine administration may be useful in hyperglycemia because of its hypoglycemic and protective effects.
Kaplan
B
B
Department of Physiology, Baskent University Faculty of Medicine, Etimesgut, Ankara, Turkey. bkaplan@mynet.com
Karabay
G
G
Zağyapan
R D
RD
Ozer
C
C
Sayan
H
H
Duyar
I
I
D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D002096:C-Peptide / Q000097:blood / Q000187:drug effects; D005947:Glucose / Q000009:adverse effects; D006168:Guinea Pigs; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000648:ultrastructure; D013438:Sulfhydryl Compounds / Q000097:blood; D013654:Taurine / Q000494:pharmacology*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D001786:Blood Glucose; D002096:C-Peptide; D013438:Sulfhydryl Compounds; D017392:Thiobarbituric Acid Reactive Substances; D013654:Taurine; D005947:Glucose